Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells

Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells

Glioblastoma represents the highest grade of brain tumors. Despite maximal resection surgery associated with radiotherapy and concomitant followed by adjuvant chemotherapy with temozolomide (TMZ), patients have a very poor prognosis due to the rapid recurrence and the acquisition of resistance to TM...

Full description

Bibliographic Details
Main Authors:	Luca X. Zampieri, Martina Sboarina, Andrea Cacace, Debora Grasso, Léopold Thabault, Loïc Hamelin, Thibaut Vazeille, Elodie Dumon, Rodrigue Rossignol, Raphaël Frédérick, Etienne Sonveaux, Florence Lefranc, Pierre Sonveaux
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	International Journal of Molecular Sciences
Subjects:	glioblastoma chemoresistance temozolomide (TMZ) cancer metabolism mitochondria PARP inhibitors
Online Access:	https://www.mdpi.com/1422-0067/22/21/11938

Similar Items

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
by: Koji eYoshimoto, et al.
Published: (2012-12-01)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
by: Milan Teraiya, et al.
Published: (2023-04-01)

STAT3-mediated upregulation of LINC00520 contributed to temozolomide chemoresistance in glioblastoma by interacting with RNA-binding protein LIN28B
by: Shuai Yuan, et al.
Published: (2022-08-01)

Isoginkgetin—A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy
by: Maria Antonietta Oliva, et al.
Published: (2022-11-01)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
by: Hannah Strobel, et al.
Published: (2019-09-01)

Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma
by: Liyun Zhong, et al.
Published: (2022-02-01)

Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
by: Jun-Hai Tang, et al.
Published: (2019-12-01)

Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling
by: Wahafu Alafate, et al.
Published: (2020-11-01)

Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems
by: Daria Petrenko, et al.
Published: (2022-05-01)

miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
by: Zongze He, et al.
Published: (2022-10-01)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
by: Monique eDontenwill, et al.
Published: (2012-10-01)

Metronomic Temozolomide (mTMZ) and Bevacizumab—The Safe and Effective Frontier for Treating Metastatic Neuroendocrine Tumors (NETs): A Single-Center Experience
by: Çağlar Ünal, et al.
Published: (2023-12-01)

A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy
by: Yanzhi Wan, et al.
Published: (2023-11-01)

A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1
by: Kai Zhao, et al.
Published: (2024-04-01)

Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
by: Yao Xiong, et al.
Published: (2020-09-01)

Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells
by: Bryan G. Harder, et al.
Published: (2019-11-01)

The effect of temozolomide on Hsp60 and Hsp70 expression in extracellular vesicles derived from U87MG glioma cells
by: Pekmez Murat, et al.
Published: (2021-09-01)

Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma
by: Woong-Jai Won, et al.
Published: (2019-01-01)

Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas
by: Zewei Tu, et al.
Published: (2022-09-01)

Nitric Oxide Prevents Glioblastoma Stem Cells’ Expansion and Induces Temozolomide Sensitization
by: Luisa Salvatori, et al.
Published: (2023-07-01)

Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity
by: Danfeng Zhang, et al.
Published: (2018-12-01)

Aloe-Emodin Overcomes Anti-Cancer Drug Resistance to Temozolomide and Prevents Colony Formation and Migration in Primary Human Glioblastoma Cell Lines NULU and ZAR
by: Sabrina Staffieri, et al.
Published: (2023-08-01)

Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma
by: Sabrina Fritah, et al.
Published: (2020-09-01)

Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells
by: Huaijin Zhang, et al.
Published: (2023-09-01)

Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC
by: Leroy A. Shervington, et al.
Published: (2022-05-01)

Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma
by: Kai Huang, et al.
Published: (2019-09-01)

Sphenopalatine Ganglion Stimulation Upregulates Transport of Temozolomide across the Blood-Brain Barrier
by: Thana N. Theofanis, et al.
Published: (2020-09-01)

Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells
by: Dana Hellmold, et al.
Published: (2023-05-01)

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development
by: Priya Bisht, et al.
Published: (2022-07-01)

Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
by: Ke Wang, et al.
Published: (2017-12-01)

Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment
by: Sicheng Wan, et al.
Published: (2023-05-01)

Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up
by: Zhuang Kang, et al.
Published: (2023-06-01)

Modified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA Methyltransferases
by: Maria Chiara Proto, et al.
Published: (2022-04-01)

High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China
by: Cui Chen, et al.
Published: (2019-04-01)

p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
by: Jiao Meng, et al.
Published: (2024-03-01)

ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression
by: Jen-Tsung Yang, et al.
Published: (2023-04-01)

Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy
by: Zahraa A. Kadhim, et al.
Published: (2022-09-01)

Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH2 Through Ultrasound to Enhance the Antitumor Efficacy and Attenuate the Toxicity for Treatment of Malignant Glioma
by: Wan Z, et al.
Published: (2021-10-01)

From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
by: Xueyuan Sun, et al.
Published: (2021-05-01)

Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells
by: Kai Zhao, et al.
Published: (2021-12-01)